Recursion Pharmaceuticals (NASDAQ: RXRX), a biotech focused on artificial intelligence (AI), became a publicly traded company in 2021 -- a time when AI did not grab nearly as much attention (if any at ...
Technology from computing powerhouse Nvidia is already hard at work inside companies at the convergence of technology and biology, including the supercomputer driving Recursion Pharmaceutical’s drug ...
Recursion, a biopharma company, uses a data-driven approach to drug discovery, launching four clinical trials and planning a fifth in oncology. Recursion's software platform, the Recursion OS, is used ...
Tech Times on MSN
Recursive launches Flint AI, free coding model that runs on laptops
Read about Recursive's Flint AI coding model, its laptop-friendly design, coding benchmarks, open-source license, and Eureka ...
Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...
Recursive Flint is a 40B MoE local coding model with 2.5B active parameters, scoring 74.2% on SWE-bench Verified.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Hosted on MSN
Where Will Recursion Pharmaceuticals Be in 5 Years?
Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results